Pharmaceutical Preparations
Industry (SEC)
Show active companies only

694 companies

ETNB
89bio, Inc.
89bio, Inc.
California
NASDAQ
ACIU
AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products.
Switzerland
NASDAQ
ACAD
ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc.
California
NASDAQ
ADCT
ADC Therapeutics SA
ADC Therapeutics SA is a clinical-stage biotechnology company, which develops antibody drug conjugates.
Switzerland
NYSE
ADTX
ADiTx Therapeutics, Inc.
California
NASDAQ
AEON Biopharma, Inc.
California
AMAG
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc.
Massachusetts
NASDAQ
ANIP
ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc.
Minnesota
NASDAQ
ASLN
ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497) is a clinical-stage oncology and immunology focused biopharma company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe.
Singapore
NASDAQ
AVEO
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
Massachusetts
NASDAQ
ABBV
AbbVie, Inc.
AbbVie, Inc.
Illinois
NYSE
ABT
Abbott Laboratories
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Illinois
NYSE
ABEO
Abeona Therapeutics, Inc.
Abeona Therapeutics, Inc.
New York
NASDAQ
ACST
Acasti Pharma, Inc.
Acasti Pharma, Inc.
Quebec, Canada
VSE
Accelerated Pharma, Inc.
Illinois
ACRX
AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc.
California
NASDAQ
AKAO
Achaogen Inc
Achaogen, Inc.
California
OTC
ACHN
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc.
Connecticut
NASDAQ
ACRS
Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc.
Pennsylvania
NASDAQ
ACT
Actavis, Inc.
The investment seeks long-term capital appreciation. The fund is an actively-managed exchange-traded fund that invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from tobacco and alcoholic beverages and companies that derive at least 50% of their net revenue from the marijuana and hemp industry or have at least 50% of their company assets dedicated to lawful research and development of cannabis or cannabinoid-related products.
New Jersey
NYSE